July 2022

Discontinuing antidepressant therapy significantly increased the risk of relapse among patients in primary care practices who felt well enough to stop taking antidepressants.

In patients with Alzheimer’s disease with clinically significant apathy, treatment with methylphenidate for 6 months in ADMET 2 was associated with a modest improvement in apathy.

Eptinezumab infusion within 1 to 6 hours of migraine onset was associated with significantly faster relief of headache pain and symptoms compared with placebo.

Researchers found that depression increased the risk of vascular disease and all-cause mortality in patients with multiple sclerosis, according to a recent study.